Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atreca, Inc.BCEL · Entity 91940 | Director | June 24, 2019 | June 24, 2019 |
| BioAtla, Inc.BCAB · Entity 879 | Director | June 18, 2025 | June 18, 2025 |
| FORUM MARKETS IncATNF · Entity 7020 | Director | July 12, 2025 | July 14, 2025 |
| Pasithea Therapeutics Corp.KTTA · Entity 7685 | Director | May 01, 2026 | May 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atreca, Inc.
Report date June 24, 2019 · Filed June 24, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 258,405 |
Reported balance
After 2019-06-24 transaction · row 1
1 source rowRow 1 · 2019-06-24 · Conversion · Acquired 8,405 · Balance 258,405 F1: The preferred stock automatically converted into Class A common stock on a 1-to-1 basis immediately upon closing of the initial public offering of the Issuer and has no expiration date. |
| Series A Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-06-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-06-24 · Conversion · Disposed 8,405 · Balance 0 F1: The preferred stock automatically converted into Class A common stock on a 1-to-1 basis immediately upon closing of the initial public offering of the Issuer and has no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The preferred stock automatically converted into Class A common stock on a 1-to-1 basis immediately upon closing of the initial public offering of the Issuer and has no expiration date.
BioAtla, Inc.
Report date June 18, 2025 · Filed June 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 78,459 |
Reported balance
After 2025-06-18 transaction · row 1
1 source rowRow 1 · 2025-06-18 · Grant · Acquired 23,500 · Balance 78,459 F1: Represents shares of Common Stock underlying a time-based restricted stock unit award ("RSU"). The RSU will vest as to 100% of the total number of shares on the earlier of (i) June 18, 2026, or (ii) the next Company annual meeting of stockholders, subject to the reporting person's continued service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Common Stock underlying a time-based restricted stock unit award ("RSU"). The RSU will vest as to 100% of the total number of shares on the earlier of (i) June 18, 2026, or (ii) the next Company annual meeting of stockholders, subject to the reporting person's continued service through the vesting date.
FORUM MARKETS Inc
Report date July 12, 2025 · Filed July 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 112,493 |
Reported balance
Holding disclosure · report date 2025-07-12 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 112,493 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.93 · Expires 2035-06-17 | Direct | 110,000 |
Reported balance
Holding disclosure · report date 2025-07-12 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 110,000 F1: As originally reported in the Reporting Person's Form 4/A filed with the SEC on June 30, 2025, the options were to vest 1/2 on each of December 17, 2025 and June 17, 2026, subject to the recipient's continued service to the Issuer. On July 12, 2025, the Board of Directors of the Company, with the recommendation of the Compensation Committee of the Board of Directors, approved the accelerated vesting of all the options effective as of such date. The options are subject to stockholder approval and (i) no options can be exercised prior to obtaining stockholder approval for the Company's 2025 Option Incentive Plan, and (ii) the outstanding options will be cancelled, if stockholder approval is not obtained. |
Filing footnotes · ownership attribution and instrument terms
F1: As originally reported in the Reporting Person's Form 4/A filed with the SEC on June 30, 2025, the options were to vest 1/2 on each of December 17, 2025 and June 17, 2026, subject to the recipient's continued service to the Issuer. On July 12, 2025, the Board of Directors of the Company, with the recommendation of the Compensation Committee of the Board of Directors, approved the accelerated vesting of all the options effective as of such date. The options are subject to stockholder approval and (i) no options can be exercised prior to obtaining stockholder approval for the Company's 2025 Option Incentive Plan, and (ii) the outstanding options will be cancelled, if stockholder approval is not obtained.
Pasithea Therapeutics Corp.
Report date May 01, 2026 · Filed May 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.84 · Expires 2036-04-30 | Direct | 152,783 |
Reported balance
After 2026-05-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-01 · Grant · Acquired 152,783 · Balance 152,783 F1: The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest in full upon the one-year anniversary of the date of grant; provided, that the Reporting Person remains a director of the Issuer through such vesting date; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest in full upon the one-year anniversary of the date of grant; provided, that the Reporting Person remains a director of the Issuer through such vesting date; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2026 Filed May 5, 2026 20:42 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantStock Option (right to buy) · Derivative | 152,783 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001213900-26-052261 · ownership.xml · derivative · entry 1 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,783 Underlying: Common Stock · 152,783 shares Expires 2036-04-30 F1 · derivative.exercise_date: The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest in full upon the one-year anniversary of the date of grant; provided, that the Reporting Person remains a director of the Issuer through such vesting date; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan). Read SEC document |
| November 28, 2025 Filed Dec 1, 2025 14:07 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | PurchaseCommon Stock | 133,333 | $0.75 | $99,999.75 |
DisclosureSEC source: 0001213900-25-116309 · ownership.xml · nonDerivative · entry 1 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,691 Read SEC document |
| October 24, 2025 Filed Oct 27, 2025 21:27 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantStock Option (right to buy) · Derivative | 242,913 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001213900-25-102682 · ownership.xml · derivative · entry 1 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 242,913 Underlying: Common Stock · 242,913 shares Expires 2035-10-23 F1 · derivative.exercise_date: The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest in full upon the one-year anniversary of the date of grant; provided, that the Reporting Person remains a director of the Issuer through such vesting date; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan). Read SEC document |
| June 18, 2025 Filed Jun 18, 2025 23:44 UTC | BioAtla, Inc. BCAB · Entity 879 | GrantCommon Stock | 23,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-088063 · ownership.xml · nonDerivative · entry 1 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,459 F1 · shares: Represents shares of Common Stock underlying a time-based restricted stock unit award ("RSU"). The RSU will vest as to 100% of the total number of shares on the earlier of (i) June 18, 2026, or (ii) the next Company annual meeting of stockholders, subject to the reporting person's continued service through the vesting date. Read SEC document |
| June 17, 2025 Filed Jun 20, 2025 20:45 UTC | FORUM MARKETS Inc ATNF · Entity 7020 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0001213900-25-056269 · ownership.xml · derivative · entry 2 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2035-06-17 F2 · price: Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors of the Issuer. F3 · derivative.exercise_date: The options vest 1/2 on each of December 17, 2025 and June 17, 2026, subject to the recipient's continued service to the Issuer. Issued under the Issuer's 2025 Option Incentive Plan. The 2025 Option Incentive Plan is subject to stockholder approval and (i) no options can be exercised prior to obtaining stockholder approval for such plan, and (ii) the outstanding options will be cancelled, if stockholder approval is not obtained. Read SEC document |
| June 17, 2025 Filed Jun 20, 2025 20:45 UTC | FORUM MARKETS Inc ATNF · Entity 7020 | GrantCommon Stock | 48,198 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-056269 · ownership.xml · nonDerivative · entry 1 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,732 F1 · shares: Represents restricted stock shares subject to time-based vesting, which vest at the rate of 1/2 of such shares on each of December 17, 2025 and June 17, 2026, subject to the recipient's continued service to the Issuer. Issued under the Issuer's 2022 Equity Compensation Plan. F2 · price: Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors of the Issuer. Read SEC document |
| June 17, 2025 Filed Jun 30, 2025 21:34 UTC Amendment | FORUM MARKETS Inc ATNF · Entity 7020 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0001213900-25-059798 · ownership.xml · derivative · entry 2 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2035-06-17 F2 · price: Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors of the Issuer. F3 · derivative.exercise_date: The options vest 1/2 on each of December 17, 2025 and June 17, 2026, subject to the recipient's continued service to the Issuer. Issued under the Issuer's 2025 Option Incentive Plan. The 2025 Option Incentive Plan is subject to stockholder approval and (i) no options can be exercised prior to obtaining stockholder approval for such plan, and (ii) the outstanding options will be cancelled, if stockholder approval is not obtained. Read SEC document |
| June 17, 2025 Filed Jun 30, 2025 21:34 UTC Amendment | FORUM MARKETS Inc ATNF · Entity 7020 | GrantCommon Stock | 44,959 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-059798 · ownership.xml · nonDerivative · entry 1 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,493 F1 · shares: Represents restricted stock shares subject to time-based vesting, which vest at the rate of 1/2 of such shares on each of December 17, 2025 and June 17, 2026, subject to the recipient's continued service to the Issuer. Issued under the Issuer's 2022 Equity Compensation Plan (the "Equity Plan"). F2 · price: Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors of the Issuer. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 23:24 UTC | FORUM MARKETS Inc ATNF · Entity 7020 | GrantCommon Stock | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-016193 · ownership.xml · nonDerivative · entry 1 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,534 F1 · shares: Represents restricted stock shares subject to time-based vesting, which vest at the rate of 1/2 of such shares on each of July 1, 2025 and December 31, 2025, subject to the recipient's continued service to the Issuer. Exempt pursuant to Rule 16b-3. F2 · price: Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors of the Issuer. Issued under the Issuer's 2022 Equity Compensation Plan. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 20:15 UTC | BioAtla, Inc. BCAB · Entity 879 | GrantCommon Stock | 16,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-073675 · ownership.xml · nonDerivative · entry 1 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,959 F1 · shares: Represents shares of Common Stock underlying a time-based restricted stock unit award ("RSU"). The RSU will vest as to 100% of the total number of shares on the earlier of (i) June 13, 2025, and (ii) the next Company annual meeting of stockholders, subject to the reporting person's continued service through the vesting date. Read SEC document |
| March 01, 2024 Filed Mar 2, 2024 02:47 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $8.34 | $0.00 |
DisclosureSEC source: 0001213900-24-019222 · ownership.xml · derivative · entry 1 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2034-02-28 F1 · derivative.exercise_date: The option award (the "Option") was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan. The shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and 33% on each successive one-year anniversary thereafter; provided, that the Reporting Person remains a director of the Issuer through such vesting date. Read SEC document |
| March 01, 2024 Filed Apr 6, 2024 01:45 UTC Amendment | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $8.13 | $0.00 |
DisclosureSEC source: 0001213900-24-030957 · ownership.xml · derivative · entry 1 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2034-02-28 F1 · derivative.exercise_price: The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on March 1, 2024, was $8.13 per share. F2 · derivative.exercise_date: The option award (the "Option") was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan. The shares of Common Stock underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and 33% on each successive one-year anniversary thereafter; provided, that the Reporting Person remains a director of the Issuer through such vesting date. Read SEC document |
| December 19, 2023 Filed Dec 20, 2023 01:24 UTC | BioAtla, Inc. BCAB · Entity 879 | PurchaseCommon Stock | 20,000 | $2.05 | $41,048.00 |
DisclosureSEC source: 0001209191-23-059284 · doc4.xml · nonDerivative · entry 1 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,459 F1 · price: The range of prices for the shares of Common Stock is from $2.005 to $2.07. The Reporting Person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| September 04, 2023 Filed Sep 6, 2023 22:55 UTC | FORUM MARKETS Inc ATNF · Entity 7020 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001213900-23-074493 · ownership.xml · derivative · entry 2 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-09-04 F1 · kind: Granted in consideration for services rendered and to be rendered as a member of the Board of Directors for the quarter ended June 30, 2023. Granted under the registrant's First Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. F1 · price: Granted in consideration for services rendered and to be rendered as a member of the Board of Directors for the quarter ended June 30, 2023. Granted under the registrant's First Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. F2 · derivative.exercise_date: The options vest at the rate of 1/12th of such options ratably on a monthly basis over the following 12 months on the last day of each calendar month (beginning September 30, 2023), subject to the Reporting Person's continued service to the Company on such vesting dates. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 22:40 UTC | BioAtla, Inc. BCAB · Entity 879 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0001209191-23-037546 · doc4.xml · derivative · entry 1 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: 100% of the total number of shares subject to the option shall vest and become exercisable on the earlier of (a) June 14, 2024 or (b) the day before the next annual meeting of stockholders, subject to the reporting person continuing to provide services through the vesting date. Read SEC document |
| June 02, 2023 Filed Jun 7, 2023 01:00 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | PurchaseCommon Stock | 30,000 | $0.43 | $12,930.00 |
DisclosureSEC source: 0001493152-23-020333 · ownership.xml · nonDerivative · entry 1 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,327,174 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.38 to $0.45 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 12:00 UTC | FORUM MARKETS Inc ATNF · Entity 7020 | PurchaseCommon Stock | 18,000 | $1.23 | $22,068.00 |
DisclosureSEC source: 0001213900-23-045386 · ownership.xml · nonDerivative · entry 1 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,129 F1 · shares: This transaction was executed in multiple trades at prices ranging from $1.15 to $1.26. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F1 · price: This transaction was executed in multiple trades at prices ranging from $1.15 to $1.26. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 28, 2022 Filed Nov 28, 2022 21:00 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantCommon Stock | 5,000 | $0.98 | $4,900.00 |
DisclosureSEC source: 0001213900-22-075491 · ownership.xml · nonDerivative · entry 1 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,287,174 Read SEC document |
| November 22, 2022 Filed Nov 22, 2022 21:10 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantCommon Stock | 5,000 | $0.99 | $4,950.00 |
DisclosureSEC source: 0001213900-22-074585 · ownership.xml · nonDerivative · entry 1 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,282,174 Read SEC document |
| October 26, 2022 Filed Oct 26, 2022 21:35 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantCommon Stock | 5,000 | $1.10 | $5,500.00 |
DisclosureSEC source: 0001213900-22-066554 · ownership.xml · nonDerivative · entry 1 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,277,174 Read SEC document |
| October 17, 2022 Filed Oct 17, 2022 22:11 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantCommon Stock | 9,000 | $1.13 | $10,170.00 |
DisclosureSEC source: 0001213900-22-064401 · ownership.xml · nonDerivative · entry 2 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,272,174 Read SEC document |
| October 17, 2022 Filed Oct 17, 2022 22:11 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantCommon Stock | 1,000 | $1.14 | $1,140.00 |
DisclosureSEC source: 0001213900-22-064401 · ownership.xml · nonDerivative · entry 1 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,263,174 Read SEC document |
| June 29, 2022 Filed Jun 30, 2022 20:15 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantCommon Stock | 5,000 | $1.00 | $5,000.00 |
DisclosureSEC source: 0001213900-22-036296 · ownership.xml · nonDerivative · entry 2 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,272,174 Read SEC document |
| June 28, 2022 Filed Jun 30, 2022 20:15 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantCommon Stock | 5,000 | $1.02 | $5,100.00 |
DisclosureSEC source: 0001213900-22-036296 · ownership.xml · nonDerivative · entry 1 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,267,174 Read SEC document |
| June 27, 2022 Filed Jun 27, 2022 20:15 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantCommon Stock | 5,000 | $1.00 | $5,000.00 |
DisclosureSEC source: 0001213900-22-035201 · ownership.xml · nonDerivative · entry 1 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,262,174 Read SEC document |
| June 23, 2022 Filed Jun 23, 2022 20:31 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantCommon Stock | 5,000 | $1.00 | $5,000.00 |
DisclosureSEC source: 0001213900-22-034621 · ownership.xml · nonDerivative · entry 1 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,257,174 Read SEC document |
| June 21, 2022 Filed Jun 22, 2022 20:30 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantCommon Stock | 652,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-034366 · ownership.xml · nonDerivative · entry 1 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,252,174 F1 · shares: Represents shares of common stock of the Issuer issued in connection with the acquisition of the ALPHA-5 Integrin, LLC on June 21, 2022. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 23:53 UTC | BioAtla, Inc. BCAB · Entity 879 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001209191-22-038172 · doc4.xml · derivative · entry 1 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-16 F1 · derivative.exercise_date: 100% of the total number of shares subject to the option shall vest and become exercisable on the earlier of (a) June 16, 2023 or (b) the next annual meeting of stockholders, subject to the reporting person continuing to provide services through the vesting date. Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 13:22 UTC | FORUM MARKETS Inc ATNF · Entity 7020 | PurchaseCommon Stock | 5,000 | $4.27 | $21,350.00 |
DisclosureSEC source: 0001213900-21-064570 · ownership.xml · nonDerivative · entry 1 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 602,574 F1 · price: This transaction was executed in multiple trades at prices ranging from $4.24 to $4.28. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 13:22 UTC | FORUM MARKETS Inc ATNF · Entity 7020 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $3.95 | $0.00 |
DisclosureSEC source: 0001213900-21-064570 · ownership.xml · derivative · entry 2 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-12-08 F2 · kind: Granted to the Reporting Person pursuant to the Issuer's 2020 Omnibus Incentive Plan in consideration for services to be rendered. Exempt from Section 16(b) of the Securities Exchange Act of 1934 under Rule 16b-3. Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 21:09 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 450 | $30.00 | $13,500.00 |
DisclosureSEC source: 0001209191-21-062747 · doc4.xml · nonDerivative · entry 1 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,459 F1 · kind: Sale effected under sales plan pursuant to Rule 10b5-1(c)(1) of the Securities Exchange Act of 1934, as amended. Read SEC document |
| September 30, 2021 Filed Oct 5, 2021 12:16 UTC | FORUM MARKETS Inc ATNF · Entity 7020 | GrantCommon Stock | 5,216 | $6.00 | $31,296.00 |
DisclosureSEC source: 0001013762-21-000203 · ownership.xml · nonDerivative · entry 1 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 597,574 F1 · kind: On September 30, 2021, the Issuer entered into a Debt Conversion Agreement with the Reporting Person, pursuant to which the parties agreed to convert an aggregate of $31,297 owed by the Registrant to the Reporting Person, for advances previously made to the Registrant's subsidiaries, into an aggregate of 5,216 shares of common stock of the Issuer. Exempt from Section 16(b) pursuant to Rule 16b-3. F2 · price: The agreed upon conversion price of the conversion of the debt described in Footnote (1) above was the greater of the closing consolidated bid price or the market price on the date the conversion agreement was entered into, and $6.00 per share, provided that because $6.00 was above the closing consolidated bid price and the market price, the conversion price was fixed at $6.00 per share. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 18:05 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 450 | $36.82 | $16,569.00 |
DisclosureSEC source: 0001209191-21-056574 · doc4.xml · nonDerivative · entry 1 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,909 F1 · kind: Sale effected under sales plan pursuant to Rule 10b5-1(c)(1) of the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 21:48 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 450 | $40.60 | $18,270.00 |
DisclosureSEC source: 0001209191-21-052295 · doc4.xml · nonDerivative · entry 1 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,359 F1 · kind: Sale effected under sales plan pursuant to Rule 10b5-1(c)(1) of the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 02, 2021 Filed Jun 22, 2022 20:30 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | GrantStock option (to acquire common stock) · Derivative | 100,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001213900-22-034366 · ownership.xml · derivative · entry 2 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 600,000 shares Expires 2031-08-02 F2 · shares: The Reporting Person was granted 100,000 stock options. The stock options have a ten-year term and vest over two years, subject to reporting person remaining employed and in good standing, one-half vesting on the first anniversary of the grant date, and the remainder vesting on the second anniversary of the grant date. Read SEC document |
| July 15, 2021 Filed Jul 20, 2021 01:25 UTC | BioAtla, Inc. BCAB · Entity 879 | SaleCommon Stock | 450 | $38.29 | $17,230.50 |
DisclosureSEC source: 0001209191-21-047324 · doc4.xml · nonDerivative · entry 1 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,809 F1 · kind: Sale effected under sales plan pursuant to Rule 10b5-1(c)(1) of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 01:27 UTC | BioAtla, Inc. BCAB · Entity 879 | GrantStock Option (right to buy) · Derivative | 12,307 | $0.00 Strike: $39.64 | $0.00 |
DisclosureSEC source: 0001209191-21-041216 · doc4.xml · derivative · entry 2 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,307 Underlying: Common Stock · 12,307 shares Expires 2031-06-15 F2 · derivative.exercise_date: 100% of the total number of shares subject to the Option shall vest and become exercisable on the earlier of (a) June 15, 2022 or (b) the next annual meeting of stockholders, subject to the Optionee continuing to provide services to the Company through the vesting date; provided however, that if the Optionee ceases to provide services to the Company prior to the vesting date for any reason other than Cause (as defined in the Plan), such Option will vest on a pro-rata basis determined by multiplying the total number of shares by a fraction, the numerator of which is the number of whole months that the Optionee provided services to the Company since the date that the award was granted, and the denominator of which is 12 months. Read SEC document |
| June 14, 2021 Filed Jun 17, 2021 01:27 UTC | BioAtla, Inc. BCAB · Entity 879 | OtherCommon Stock | 5,388 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-041216 · doc4.xml · nonDerivative · entry 1 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,259 F1 · kind: Distribution of the Issuer's shares of Common Stock by Himalaya Parent LLC, of which the reporting person is a member, for no consideration. Read SEC document |
| April 07, 2021 Filed Apr 8, 2021 12:00 UTC | FORUM MARKETS Inc ATNF · Entity 7020 | GrantCommon Stock | 22,585 | $6.14 | $138,671.90 |
DisclosureSEC source: 0001213900-21-020733 · ownership.xml · nonDerivative · entry 1 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 592,358 F1 · kind: Issued in consideration for accrued compensation due for services rendered as Co-Executive Chairman of the Issuer. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt from Section 16(b) pursuant to Rule 16b-3. F1 · price: Issued in consideration for accrued compensation due for services rendered as Co-Executive Chairman of the Issuer. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt from Section 16(b) pursuant to Rule 16b-3. Read SEC document |
| June 24, 2019 Filed Jun 24, 2019 20:51 UTC | Atreca, Inc. BCEL · Entity 91940 | ConversionSeries A Preferred Stock · Derivative | 8,405 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-038796 · doc4.xml · derivative · entry 2 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 8,405 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The preferred stock automatically converted into Class A common stock on a 1-to-1 basis immediately upon closing of the initial public offering of the Issuer and has no expiration date. F1 · derivative.exercise_date: The preferred stock automatically converted into Class A common stock on a 1-to-1 basis immediately upon closing of the initial public offering of the Issuer and has no expiration date. F1 · derivative.expiration_date: The preferred stock automatically converted into Class A common stock on a 1-to-1 basis immediately upon closing of the initial public offering of the Issuer and has no expiration date. Read SEC document |
| June 24, 2019 Filed Jun 24, 2019 20:51 UTC | Atreca, Inc. BCEL · Entity 91940 | ConversionClass A Common Stock | 8,405 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-038796 · doc4.xml · nonDerivative · entry 1 STEINMAN LAWRENCE · CIK 0001132679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,405 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The preferred stock automatically converted into Class A common stock on a 1-to-1 basis immediately upon closing of the initial public offering of the Issuer and has no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.